TIDMAGL
Angle PLC
11 November 2021
For immediate release 11 November 2021
ANGLE plc ("the Company")
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATION AT
NATIONAL CANCER RESEARCH INSTITUTE (NCRI) FESTIVAL
Study in metastatic prostate cancer presented at NCRI Festival
demonstrates longitudinal analysis of CTCs harvested using the
Parsortix system is predictive of treatment response
KLK2 gene expression on CTCs found to be a more effective
biomarker for assessing likelihood of cancer progression than
current standard of care
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that a poster presentation
showcasing the Parsortix(R) system was presented yesterday at the
National Cancer Research Institute (NCRI) Festival, being held 8-12
November 2021. The poster showcases findings from a Barts Cancer
Institute study in metastatic prostate cancer which undertook
circulating tumour cell (CTC) analysis to evaluate docetaxel drug
treatment response and resistance markers.
Longitudinal CTC sampling was performed using the Parsortix
system in 56 patients. The samples were taken before patients
started docetaxel treatment, during treatment, and after completing
all doses over a period of 6-8 months. A total of 205 CTC samples
were analysed for changes in CTC number, phenotype, and mRNA gene
expression.
Multiplex qPCR analysis, using a custom designed 32 gene panel
of CTC mRNA revealed that patients with disease progression who
have worse predicted survival rates had high expression of the KLK2
gene at each blood collection time point and that this was
significantly more predictive than the current standard of care for
assessing the likelihood of progression, which is based on blood
PSA levels. These findings are significant as they highlight KLK2
as a possible alternative and a better biomarker for prostate
cancer prognosis.
This study concludes that longitudinal analysis of CTCs isolated
using the Parsortix system can predict whether a patient is
resistant or developing resistance to treatment with docetaxel. As
such, it could be used as an early biomarker for treatment
response. Study findings could enable doctors to detect early on,
and without invasive procedures, if a treatment is working and
switch to alternatives if it is not.
Prostate cancer is the leading cause of cancer in men and
accounts for 13% of all new cancer cases in the United States. In
2021, the National Cancer Institute estimates that there will be
248,500 new cases in the United States with an additional 3.2
million men living with the disease. The current standard of care,
transrectal ultrasound-guided prostate tissue biopsy, is an
invasive procedure associated with clinical complications where 32%
of patients will experience moderate side effects and 1.4% of
patients experience major complications. This includes post-biopsy
sepsis in 2-5% of cases with up to 25% requiring admission to ICU.
Liquid biopsy offers the potential for safe, cost-effective
longitudinal monitoring of tumour evolution and disease progression
to track mutations responsible for therapy resistance and identify
biomarkers for targeted treatment selection.
Caitlin Davies, study author and PhD research student at Barts
Cancer Institute, Queen Mary University of London, UK,
commented:
"This insight into how CTC dynamics lead to reduced
progression-free and survival times is vital for clinicians. It
will enable them to make early changes of treatment from docetaxel
to an alternative, which may significantly improve patients'
chances of long-term survival. Furthermore, analysis of CTC gene
expression and detection of genes associated with resistance to
docetaxel may aid the development of a new generation of
therapies.
Professor Hashim Ahmed, Chair of the NCRI Prostate Group and
Professor of Urology at Imperial College London, UK, who was not
involved in the research, said:
"These are promising results and have the potential to change
clinical practice, if they are confirmed by further research.
Assessing the responsiveness of an individual patient's tumour to
docetaxel treatment by means of blood tests will enable clinicians
to personalise cancer treatment more easily and effectively,
without the patient having to undergo invasive procedures such as
tissue biopsies. It could also help to avoid patients undergoing
unpleasant systemic treatments that are going to be
unsuccessful."
ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased that Barts has presented this promising data
showcasing longitudinal analysis using the Parsortix system. Their
findings not only demonstrated the Parsortix system's potential to
guide treatment decisions but also its ability to help identify new
biomarkers for assessing likelihood of progression in prostate
cancer and as possible targets for new drug therapy. This evidence
provides further support for our pharma services business which
offers longitudinal analysis for drug trials in multiple cancers
and for our planned studies to develop a prostate cancer assay to
offer as a laboratory developed test from our own
laboratories."
The poster and abstract are available at
https://angleplc.com/library/publications/ .
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Max Jones, Thomas Bective +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen; as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and a 200 patient
clinical verification study has now completed enrolment.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) platform and is
based on a patented flow through array technology. It provides for
low cost, highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. The HyCEAD system is extremely sensitive and is ideal for
measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test
to achieve best in class accuracy (AUC-ROC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
49 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of Parsortix in cancer drug trials and, once the
laboratories are accredited and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFUEFSEFSEFF
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024